EEF2K and triple-negative breast carcinoma: They reported significant in vivo tumor integration of miR-329 and inhibition of the eukaryotic elongation factor-2 kinase (eEF2K) protein in multiple triple-negative breast cancer (TNBC) models with pronounced anti-tumor efficacy and without any side effects in mice.